当检测不循常规:感染性疾病诊断中不可知mNGS的监管挑战
本文综述了基于宏基因组二代测序(mNGS)的不可知检测在感染性疾病诊断中的验证与监管挑战,指出其作为实验室自建检测(LDT)限制了患者可及性,而FDA体外诊断授权路径中的逐病原体性能表征要求难以适配mNGS的不可知特性,并讨论了生物信息学流程、参考数据库、监管沟通、标签、临床报告及质量体系对齐等实际问题。
要点
- mNGS不可知检测受LDT分类限制,患者可及性有限。
- FDA授权路径中逐病原体性能表征要求难以适配mNGS不可知特性。
- 生物信息学流程与参考数据库是核心验证挑战。
核心结论
- mNGS的不可知特性使现行逐病原体监管要求难以直接适用,需探索模块化、基于组件的监管方法。
研究设计与样本
- 本文为小型综述,综合了mNGS诊断验证与监管挑战,并描述实验室与开发者当前如何应对可用路径。
主要发现
- 现有指南推荐类似靶向分子检测的逐病原体性能表征,涉及固定分析物与稳定检测阈值,难以适配mNGS。
- 生物信息学流程与参考数据库在分析验证中具有核心作用。
关键数值与推荐
- 现有指南推荐逐病原体性能表征,类似靶向分子检测的固定分析物与稳定检测阈值。
临床怎么用
- 实验室与开发者应关注监管沟通、标签、临床报告及mNGS检测与现有质量体系框架的对齐。
局限性
- 本文为小型综述,未报告原始研究数据或系统检索范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metagenomic next-generation sequencing (mNGS) enables agnostic detection of bacteria, viruses, fungi, and parasites from clinical specimens. Patient access is restricted due to their current regulatory classification as Laboratory Developed Tests, which are offered by a limited number of laboratories. While patient access may be expanded through Food and Drug Administration authorization of mNGS-based in vitro diagnostics, some regulatory requirements for achieving this classification can be challenging to apply due to the agnostic nature of mNGS. For example, existing guidelines recommend organism-by-organism performance characterization similar to targeted molecular tests involving fixed analytes with stable detection thresholds. This minireview synthesizes validation and regulatory challenges unique to mNGS-based diagnostics and describes how laboratories and developers currently navigate available pathways. We focus on core analytical and clinical validation challenges, including discussion on the central role of bioinformatics pipelines and reference databases. We then summarize practical considerations for regulatory engagement, labeling, clinical-facing reporting, and alignment of mNGS assays to existing quality system frameworks. Finally, we outline future oversight considerations, including the need to distinguish mNGS from multiplexed PCR paradigms and the potential value of modular, component-based regulatory approaches that separately evaluate reagents, instruments, software, and databases, enabling system-level oversight rather than organism-by-organism validation. Together, these considerations aim to support risk-appropriate, scalable oversight, and accelerate adoption of mNGS in clinical microbiology.
引用
- Gauthier NPG, Kapoor V, Gaston DC, et al. When tests don't fit the rules: regulatory challenges for agnostic metagenomic next-generation sequencing in infectious diseases diagnostics. J Clin Microbiol. 2026. PMID: 42720301. doi:10.1128/jcm.00987-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。